Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Surufatinib Plus Sintilimab and Chemotherapy in Gastric and GEJ Adenocarcinoma
NCT06447636Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- May 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Started Sep 2024; status: active, not recruiting.
02
Drugs
surufatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06447636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447636.